Lilly Eli & Co Stock Price, News & Analysis

Eli Lilly and Company (NYSE: LLY) announced on October 28, 2025 its roster of seven Team USA athletes for the Olympic and Paralympic Winter Games Milano Cortina 2026, naming Elana Meyers Taylor, Madison Chock, Erin Jackson, Maddie Mastro, Mikaela Shiffrin, Oksana Masters and Jack Wallace.

Lilly reiterated its Milestones into Meaning™ program: for every U.S. Olympic or Paralympic medal, World Record or Olympic/Paralympic Record, Lilly will donate $5,000 to U.S. nonprofits that expand health care access. The program donated $2.6 million to 24 organizations at Paris 2024 and will expand to benefit 26 U.S. organizations in Milano Cortina 2026.

Eli Lilly (NYSE: LLY) announced on October 27, 2025 that the U.S. FDA approved a single‑injection, once‑monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab‑mrkz) for adults with moderately to severely active ulcerative colitis.

The approval follows an EU authorization and is supported by a Phase 1 bioequivalence study comparing one 200 mg/2 mL injection to two 100 mg/1 mL injections. The single‑injection, citrate‑free maintenance dose will be available in the U.S. via prefilled pen or syringe in early 2026. Omvoh retains existing safety warnings for allergic reactions, infections, and liver problems.

Eli Lilly and Company (NYSE: LLY) declared a fourth-quarter 2025 dividend of $1.50 per share on outstanding common stock.

The dividend is payable on December 10, 2025 to shareholders of record at the close of business on November 14, 2025.

Eli Lilly (NYSE: LLY) announced on Oct 27, 2025 a nationwide partnership with Shaquille O'Neal to expand the "Don't Sleep on OSA" campaign and raise awareness of moderate-to-severe obstructive sleep apnea (OSA).

The initiative highlights that an estimated 24 million U.S. adults may have OSA, outlines common symptoms (loud snoring, choking/gasping, daytime sleepiness), and directs people to DontSleepOnOSA.com to learn more and talk to their healthcare provider.

Eli Lilly (NYSE: LLY) reported Phase 3b LUCENT-URGE results showing early, sustained improvement in bowel urgency for adults with moderately to severely active ulcerative colitis treated with Omvoh (mirikizumab‑mrkz).

Key outcomes: 55% reduction in daily bowel urgency episodes by Week 12 (maintained at Week 28), 52% reduction in urgency severity by Week 28, and increase in patients able to delay a bowel movement ≥15 minutes from 4.1% at baseline to 29.7% at Week 28. Safety was consistent with prior LUCENT data: 5.2% serious adverse events and 4.7% discontinuations due to adverse events. Results will be presented at ACG Oct 24–29, 2025.

Eli Lilly (NYSE:LLY) agreed to acquire Adverum Biotechnologies for $3.56 cash per share plus one CVR, with the CVR payable up to $8.91 for total potential consideration of $12.47 per share. The deal funds a tender offer and a second-step merger, is expected to close in Q4 2025, and requires a majority tender. Lilly provided a secured $65 million promissory note to support Adverum operations pre-close. Adverum's lead asset, Ixo-vec, is a Phase 3 intravitreal gene therapy for wet AMD (ARTEMIS trial completed screening) with Fast Track, RMAT, EMA PRIME, and UK Innovation Passport designations.

Lilly (NYSE: LLY) reported 52-week Phase 3 BRAVE-AA-PEDS results showing once-daily oral baricitinib 4 mg produced substantial hair regrowth in adolescents (ages 12 to <18) with severe alopecia areata.

Key one-year outcomes: 54.1% achieved ≥80% scalp hair coverage (SALT ≤20) on 4 mg versus 31% on 2 mg; 41.2% on 4 mg achieved ≥90% scalp coverage (SALT ≤10). In the severe-disease subgroup (SALT 50–94), 71% on 4 mg achieved successful regrowth. Eyebrow and eyelash regrowth rates were also higher on 4 mg. Safety was consistent with prior trials; no deaths, opportunistic infections, MACEs, or VTEs were reported.

Lilly plans to submit these adolescent data to global regulators for a potential label update for Olumiant and to enroll younger children in BRAVE-AA-PEDS.

Eli Lilly (NYSE: LLY) reported Phase 3 ADjoin extension data on Oct. 24, 2025 showing EBGLYSS (lebrikizumab-lbkz) maintained high disease control when switched from monthly maintenance dosing to a single 250 mg injection every eight weeks (Q8W).

Key results: EASI-75 rates were 79% Q8W vs 86% Q4W; IGA 0,1 rates were 62% Q8W vs 73% Q4W. No new safety signals or increased immunogenicity were observed. Lilly submitted these data to the FDA seeking a potential label update to offer an every-eight-week maintenance option; an every-twelve-week study is underway.

Lilly (NYSE: LLY) announced primary overall survival results from the Phase 3 monarchE trial showing two years of adjuvant Verzenio (abemaciclib) plus endocrine therapy reduced the risk of death by 15.8% versus endocrine therapy alone (7-year OS: 86.8% vs 85.0%; HR 0.842; 95% CI 0.722–0.981; 2-sided p=0.027) with median follow-up of 6.3 years. The regimen also showed sustained benefits in invasive disease-free survival and distant relapse-free survival, and 32% fewer patients were living with metastatic disease (6.4% vs 9.4%). Safety was consistent with prior analyses; data were published in Annals of Oncology and presented at ESMO on Oct 17, 2025.